Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 30
- Registration Number
- NCT06624475
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 30
- Registration Number
- NCT06599619
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
- Conditions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Replimune Inc.
- Registration Number
- NCT06590480
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06581406
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸HonorHealth Research Insisute, Scottsdale, Arizona, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06572722
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 800
- Registration Number
- NCT06561386
- Locations
- 🇺🇸
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
🇺🇸Local Institution - 0369, Canton, Ohio, United States
🇧🇷Local Institution - 0382, Fortaleza, Ceará, Brazil
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06561087
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 156
- Registration Number
- NCT06554613
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 134
- Registration Number
- NCT06544655
- Locations
- 🇨🇦
Local Institution - 0017, Toronto, Ontario, Canada
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Local Institution - 0003, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.